Home › Companies › GLSI

Greenwich LifeSciences

Market cap $274M 14.7M shares (10-Q, Nov 6, 2026) × $18.70 close Nov 17, 2026

Most recent annual filing: 2026-06-01

Catalyst timeline

2 trackedQuarter catalyst calendar →
  1. Insider lock-up corporate updateJan 31, 2027Insider lock-up corporate update, Jan 31, 2027, routine
  2. GLSI insider lock-up corporate updateJan 31, 2027GLSI insider lock-up corporate update, Jan 31, 2027, routine

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (1 active programs)

Capital (as filed)

Cash
$5.9M cash, equivalents and restricted cash · Sep 30, 2026 (10-Q)
Operating cash flow
−$3.0M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
As stated in coverage
$5.9M cash per the update of Nov 16, 2026 — the company's own words as read there, not the filed figure

Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.

Biotech Distilled coverage (14)

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.

Verdict history (14 calls)

Every verdict Biotech Distilled has published on Greenwich LifeSciences, oldest first — the full history, never a selection. How calls are scored: the track record.

  1. Watch Greenwich LifeSciences (GLSI): Scientific Due Diligence for GLSI-100 Science is intriguing but the Dilution Gap is terrifying; wait for the inevitable capital raise before entering this binary bio-lottery ticket.
  2. Hold Update: Greenwich LifeSciences (GLSI) - The Boring News That Actually Matters FDA approval of commercial GP2 vials de-risks CMC and signals management conviction, but solvency risk remains; hold and accumulate on dips.
  3. Hold UPDATE: Greenwich Lifesciences (GLSI) - The ATM Just Printed $7 Million. Is the Cash Crunch Over? ATM raise of $7M doubles cash to $12.5M and significantly reduces near-term insolvency risk, keeping the bull case intact while dilution continues.
  4. Hold UPDATE: Greenwich LifeSciences (GLSI) - Mark Your Calendars. The Steering Committee Speaks. AACR abstract acceptance with full Steering Committee co-authorship provides a concrete data timeline and signals clinical credibility; maintain hold while awaiting April readouts.
  5. Hold UPDATE: Greenwich LifeSciences (GLSI) - Foot on the Gas. Screening Rate Jumps 33%. 33% jump in screening rate to 800 patients/year accelerates the timeline to the 14-event interim analysis; clinical machinery is executing well.
  6. Hold UPDATE: Greenwich LifeSciences (GLSI) - The Data Firehose 83% recurrence reduction in open-label arm and statistically significant DTH immune response data reinforce the bullish mechanism thesis; hold and accumulate on dips ahead of AACR.
  7. Hold UPDATE: Greenwich LifeSciences (GLSI) — The Protocol Pivot, the Patent Stretch, and a Late 10-K FDA protocol amendment combining HLA populations and new solely-owned patent to 2045 are bullish, but late 10-K, Nasdaq notice, dual-auditor situation, and 35% R&D jump add a new governance yellow flag.
  8. Hold UPDATE: Greenwich LifeSciences (GLSI) — The 10-K Lands, ASCO Confirms the Mechanism 10-K filing closes Nasdaq compliance overhang and two consecutive Steering Committee posters at p<0.001 across HLA types support the protocol amendment, though audited burn is materially higher than January narrative.
  9. Speculative buy speculative UPDATE: Greenwich LifeSciences (GLSI) — The 10-Q Decodes the 17% Drop Q1 10-Q reveals 129% R&D jump, material weaknesses in internal controls, and going-concern language, causing a 17% drop that arguably re-prices the governance overhang and makes the -17% dip a speculative entry point.
  10. Speculative buy speculative UPDATE: Greenwich LifeSciences (GLSI) — Europe Falls in Line. The Interim Clock Just Sped Up. EMA approval of the combined-HLA protocol harmonizes all 170-180 global sites and unlocks the European non-HLA-A*02 waitlist, mechanically compressing the timeline to the 14-event interim analysis.
  11. Speculative buy speculative UPDATE: Greenwich LifeSciences (GLSI) — The Interim Just Got Rewritten. Stock -26% in Two Sessions. Trial redesign moves design HR from 0.3 to 0.55 and doubles the interim trigger to 28 events, materially delaying the readout but improving statistical power; the binary is intact but further out.
  12. Speculative buy speculative UPDATE: Greenwich LifeSciences (GLSI) — The Lock-Up Slides Again. September 30 Is Off the Board. Seventh sequential lock-up extension to January 31, 2027 removes the September supply overhang and partnership language names royalty/strategic-investor structures, signaling deal intent.
  13. Speculative buy speculative UPDATE: Greenwich LifeSciences (GLSI) — The Burn Guide-Down Was Real. The Control Problems Weren't Fixed. Q2 burn of ~$1.94M validated management's guide and ATM activity collapsed to near zero, extending runway, but material weaknesses remain unremediated and related-party reimbursements doubled YoY.
  14. Watch UPDATE: Greenwich LifeSciences (GLSI) - The Burn Guide Held. The Bills Didn't Get Paid. Q3 in-guide burn was achieved only via a $1.9M payables build; cash of $5.90M is below $7.65M current liabilities, equity is negative, ATM sat idle, and a financing before the interim now looks unavoidable at an unknown price.

Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.

Filings & releases (16)

SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from Apr 30, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →

2 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)